RB-383 Xenograft Model Service for Retinoblastoma

The RB-383 xenograft model offers a robust preclinical platform for evaluating novel therapeutic strategies against retinoblastoma, faithfully recapitulating the molecular and histopathological features of this aggressive pediatric intraocular malignancy. At Alfa Cytology, we specialize in delivering clinically translatable preclinical tumor model services, and our RB-383 xenograft program is designed to accelerate your retinoblastoma drug development pipeline with rigorous methodology and comprehensive endpoint analysis.

Overview of RB-383 Xenograft Model for Retinoblastoma

Retinoblastoma is the most common malignant intraocular tumor of childhood, arising from the immature retina due to biallelic inactivation of the RB1 tumor suppressor gene on chromosome 13q14. The RB-383 cell line represents a well-established human retinoblastoma model that exhibits RB1 promoter hypermethylation and MYCN amplification, genetic alterations frequently observed in primary patient tumors. When engrafted into immunodeficient hosts, RB-383 cells form xenograft tumors that maintain the small epithelioid morphology, high nuclear-to-cytoplasmic ratio, and cluster-based growth patterns characteristic of human retinoblastoma, providing a physiologically relevant system for preclinical pharmacology and toxicology studies.

The RB-383 xenograft model supports both subcutaneous and orthotopic implantation strategies. Subcutaneous xenografts enable straightforward tumor volume monitoring and facile access for serial biopsies, whereas orthotopic intraocular implantation more faithfully recapitulates the tumor microenvironment, retinal vasculature interactions, and drug penetration barriers encountered in clinical disease. This model has been extensively utilized in chick chorioallantoic membrane (CAM) assays and rodent systems to evaluate chemotherapeutic agents, photodynamic therapy photosensitizers, and targeted molecular compounds, demonstrating robust tumorigenicity and dissemination potential suitable for high-throughput drug screening and personalized medicine approaches.

• Efficacy Testing: Evaluating the in vivo anti-tumor activity of novel compounds, small molecules, biologics, or combination therapies targeting retinoblastoma.
• Mechanistic Studies: Investigating the complex molecular pathways driving retinoblastoma progression and epigenetic silencing, and how treatments intersect with these pathways.
• Biomarker Discovery: Identifying and validating potential biomarkers for treatment response or resistance in a controlled in vivo environment.

Figure 1. Salinomycin is active against retinoblastoma cells in vitro. (Li, Jing, et al., 2021)

Cell Line Information: RB-383

The RB-383 cell line is a well-established human retinoblastoma cell line with comprehensive molecular characterization. Its ability to retain epigenetic RB1 silencing and MYCN amplification makes it unique among available retinoblastoma cell lines and essential for aggressive subtype research.

Our Services

Alfa Cytology leverages the RB-383 retinoblastoma cell line to construct validated xenograft platforms that meet the stringent demands of modern oncology drug development. Our integrated service portfolio encompasses model establishment, in vivo pharmacology, biomarker analysis, and comprehensive histopathological evaluation, ensuring that your preclinical retinoblastoma program proceeds with scientific rigor and regulatory foresight from inception through IND-enabling studies.

Workflow of RB-383 Xenograft Model Construction

The construction of the RB-383 xenograft model follows a standardized, quality-controlled workflow optimized for reproducible tumor engraftment and longitudinal therapeutic assessment. At Alfa Cytology, we adhere to an optimized, multi-step workflow to ensure maximum take rates and reproducible growth kinetics. The streamlined workflow involves:

1. Cell Preparation and Quality Control: RB-383 cells are expanded under standard culture conditions and validated for identity via STR profiling, mycoplasma negativity, and RB1 promoter methylation status confirmation. Cells are harvested at logarithmic growth phase, washed, and resuspended in serum-free medium supplemented with 50% Matrigel to enhance engraftment efficiency and maintain histological fidelity.
2. Host Selection and Acclimation: Immunodeficient recipient animals---typically athymic nude mice (Hsd: Athymic Nude-Foxn1nu) or severe combined immunodeficiency (SCID) mice---are acclimated for 7 days under pathogen-free conditions. Animal health status is verified prior to tumor cell inoculation.
3. Tumor Cell Inoculation: For subcutaneous models, 1.0--10.0 x 10^6 RB-383 cells in 200 uL cell suspension are injected into the flank or dorsal region. For orthotopic intraocular models, cells are microinjected into the vitreous or subretinal space of newborn or adult immunodeficient rodents under microscopic guidance, preserving ocular anatomy.
4. Tumor Monitoring and Randomization: Implanted animals are monitored daily for tumor palpability. Tumor dimensions are measured via digital calipers (subcutaneous) or non-invasive imaging modalities including scanning laser ophthalmoscopy (SLO), optical coherence tomography (OCT), and bioluminescence imaging (orthotopic). Upon reaching a mean tumor volume of approximately 80 mm^3, animals are randomized into treatment cohorts.
5. Therapeutic Intervention and Dosing: Test articles are administered according to predefined protocols (intravenous, intraperitoneal, intra-arterial, intravitreal, or topical routes). Dosing schedules, formulation vehicles, and route selection are optimized based on compound physicochemical properties and target engagement requirements.
6. Endpoint Analysis and Sample Collection: At study termination, tumors and relevant tissues (eye, retina, optic nerve, brain, liver, lung) are harvested for comprehensive analysis. Endpoints include tumor volume regression, histopathology (H&E, immunohistochemistry), immunofluorescence, TUNEL apoptosis quantification, microvessel density assessment, and molecular biomarker profiling.

Figure 2: Schematic workflow illustrating the derivation and construction of the RB-383 Xenograft Model at Alfa Cytology.

Case Study-RB-383 Xenograft Model Development

Alfa Cytology has successfully established and validated the RB-383 xenograft model across multiple immunodeficient host platforms. In a representative preclinical engagement, the RB-383 xenograft model was established to evaluate the efficacy of a novel therapeutic candidate against MYCN-amplified retinoblastoma. Tumor-bearing immunodeficient mice were randomized into control and treatment cohorts upon reaching palpable tumor volumes. Longitudinal monitoring demonstrated dose-dependent tumor growth inhibition, with treated animals exhibiting significant reductions in tumor burden compared to vehicle controls. Histopathological analysis revealed decreased Ki-67 proliferation indices and increased apoptotic cell populations in responder tumors. Comprehensive pharmacokinetic and pharmacodynamic data, including biomarker modulation and toxicity profiles, are available upon formal inquiry to support your specific program requirements.

Why Choose Alfa Cytology?

Alfa Cytology distinguishes itself as a specialized preclinical CRO partner through unwavering commitment to scientific excellence, operational transparency, and client-centric program design. Our RB-383 xenograft service embodies these principles, delivering actionable data to advance your retinoblastoma therapeutic pipeline.

• Verified Cell Line Integrity: Validated RB-383 cell line authentication and mycoplasma screening ensure model integrity from study initiation.
• Dual Implantation Expertise: Dual implantation expertise in both subcutaneous and orthotopic intraocular xenograft systems accommodates diverse pharmacological objectives.
• Integrated Imaging Capabilities: Integrated in vivo imaging capabilities (SLO/OCT, bioluminescence, ultrasound) enable non-invasive longitudinal tumor monitoring.
• Customizable Endpoint Portfolios: Customizable endpoint portfolios encompassing histopathology, immunohistochemistry, biomarker analysis, and toxicology assessment.
• Dedicated Study Directors: Dedicated study directors with deep expertise in pediatric oncology models provide real-time scientific consultation and adaptive protocol refinement.
• Streamlined Project Timelines: Streamlined project timelines and proactive communication frameworks ensure transparent milestone delivery and data interpretation support.

Contact Us

Advance your retinoblastoma therapeutic program with Alfa Cytology's specialized RB-383 xenograft model services. Our team of preclinical oncology experts is ready to discuss your specific study requirements, design customized protocols, and deliver the high-quality data you need to move confidently toward your next development milestone. Please reach out to us today via our inquiry form or email to learn more about our RB-383 Xenograft Model services.

For research use only. Not intended for any clinical use.